ArticleClinical cardiology2026
Early Outcomes of Real-World Aortic Valve Replacement With RESILIA Tissue in the Chinese Population.
Article in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAortic valve replacement (AVR) with the INSPIRIS RESILIA aortic valve (Edwards Lifesciences, Irvine, CA) has established durability and promising outcomes. However, real-world safety and functional performance data remain limited. This study reported early outcomes in the Chinese population.
methodsThis prospective, multicenter, single-arm, post-market, real-world study enrolled patients scheduled for elective AVR using the study valve. Safety outcomes included all-cause death, study valve-related death, structural valve deterioration (SVD), non SVD, reoperation on the study valve, major bleeding, and thromboembolic events. Effectiveness outcomes included valve hemodynamic performance and New York Heart Association (NYHA) class.
resultsA total of 250 patients underwent study valve implantation, with 238 completing 1-year follow-up (mean follow-up duration: 448.2 ± 162.50 days). The mean age was 58.5 ± 9.17 years, with 11.4% undergoing concomitant aortic root/annular enlargement. The 1-year freedom from all-cause death and freedom from reoperation on the study valve were 98.0% and 99.2%, respectively. All deaths were assessed as unrelated to the study device. Incidence of complications included thromboembolic events (2.4%), major bleeding (4.4%), endocarditis (0.4%), and new permanent pacemaker implantation (0.4%) at 1 year. Two patients (0.8%) required reoperation on the study valve. No SVD was observed. At 1-year post-operation, no severe aortic regurgitation (AR) occurred, while 1 patient (0.4%) developed moderate AR. Three patients (1.3%) had mild paravalvular leakage. Functional status improved with 100% of patients having a NYHA Class I/II at 1 year.
conclusionINSPIRIS RESILIA aortic valve shows favorable 1-year safety profiles and stable hemodynamics in Chinese patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.